We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies. Close

Weighing access against profit

Intellectual Property Magazine

Weighing access against profit

The USgovernment has sued Gilead Sciences over the patent rights to use Truvada for pre-exposure prophylaxis

Truvada is an HIV medication sold by Gileadand has been on the market since 2004. In November 2019, the US federalgovernment sued Gilead for infringement of patents owned by its Department ofHealth & Human Services regarding using Truvada and other such HIVmedications for a specific type of treatment regimen called pre-exposureprophylaxis (PrEP). 1 Unlike the conventional use of HIV drugs inpatients infected with HIV, PrEP is the use of HIV drugs (by daily dosing) onpeople who do not have HIV, but who are at very high risk of getting infectedwith HIV. Should such as a person be exposed to HIV, the drug alreadycirculating in their body would immediately arrest the viral infection process.

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, please enter your details below to log in.

Enter your email address to log in as a user on your corporate account.
Remember me on this computer

Not yet an i-law subscriber?


Request a trial Find out more